Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
MyHealthChecked (LONL MHC) shares are rising on Wednesday after achieving ISO 15189:2012 accreditation across the Company's COVID-19 testing service.
The accreditation was granted following assessments by the United Kingdon Accreditation Service (UKAS), ensuring that the laboratories used as part of the company's COVID-19 testing service deliver high-quality service and meet the relevant legal requirements.
Penny McCormick, CEO of MyHealthChecked, said: “We are delighted to now have in place accreditation across our COVID-19 testing service, which is a clear sign to our existing customers and potential new customers that our medical laboratories and operational systems are extremely rigorous and structured around best possible practice within the industry.
“I am incredibly proud of the MyHealthChecked team for maintaining these high standards, ensuring that we offer a reliable and efficient service to all of our partners.”
MyHealthChecked's share price has moved 3.29% above Tuesday's close, to 3.92p.
MyHealthChecked shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are MHC shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .